Actinium Pharmaceuticals (ATNM) Net Margin (2021 - 2026)

Actinium Pharmaceuticals (ATNM) posted quarterly Net Margin of 7014.44% for Q3 2025, up 79.2% quarter-over-quarter from 33724.44% in Q3 2022.

Actinium Pharmaceuticals (ATNM) Net Margin (2021 - 2026) Analysis & Trends

Actinium Pharmaceuticals (ATNM) has reported Net Margin for 3 consecutive years, with 7014.44% the latest figure, recorded in Q3 2025.

In Q3 2025, Net Margin changed N/A year-over-year to 7014.44%; the TTM figure through Dec 2025 stood at 26271.11% (changed N/A YoY), while the FY2025 annual figure was 36987.78%, changed N/A from the prior year.
Net Margin grew to 7014.44% in Q3 2025 per ATNM's latest filing, from 33724.44% in the prior quarter.
Across five years, Net Margin topped out at 559.36% in Q1 2022 and bottomed at 34826.09% in Q4 2021.
Historically, Net Margin has averaged 12392.59% across 3 years, with a median of 4885.55% in 2025.
On a YoY basis, Net Margin climbed as much as 31942 bps in 2022 and fell as far as 3096779 bps in 2022.
Actinium Pharmaceuticals' Net Margin stood at 34826.09% in 2021, then rose by 3 bps to 33724.44% in 2022, then soared by 79 bps to 7014.44% in 2025.
Business Quant data shows ATNM's Net Margin at 7014.44% in Q3 2025, 33724.44% in Q3 2022, and 17493.33% in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	32.99%
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	30.23%
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	31.16%
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-539.31%
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	13.90%
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	12.74%
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-16.51%
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-3.12%
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	12.09%
10	Actinium Pharmaceuticals	35.01 Mn	35.01 Mn	-	79.72%

Download Data